This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coukos, G. Articles by Molnar-Kimber, K. L. Search for Related Content PubMed PubMed Citation Articles by Coukos, G. Articles by Molnar-Kimber, K. L.

Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer¹

Divisions of Gynecologic Oncology [G. C., I. B., S. C. R.] and Reproductive Biology [A. M.], Department of Obstetrics and Gynecology; Division of Pulmonary Medicine/Critical Care, Department of Medicine [S. M. A.]; and the Thoracic Oncology Laboratory, Department of Surgery [E. H. K., D. C., L. R. K., K. L. M-K.], University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104

Epithelial ovarian cancer (EOC) remains localized within the peritoneal cavity in a large number of patients, lending itself to i.p. approaches of therapy. In the present study, we investigated the effect of replication-selective herpes simplex virus-1 (HSV-1) used as an oncolytic agent against EOC and the use of human teratocarcinoma PA-1 as carrier cells for i.p. therapy. HSV-1716, a replication-competent attenuated strain lacking ICP34.5, caused a direct dose-dependent oncolytic effect on EOC cells in vitro. A single i.p. administration of 5 x 10⁶ plaque-forming units resulted in a significant reduction of tumor volume and tumor spread and an increase in survival in a mouse xenograft model. PA-1 cells supported HSV replication in vitro and bound preferentially to human ovarian carcinoma surfaces compared with mesothelial surfaces in vitro and in vivo. In comparison with the administration of HSV-1716 alone, irradiated PA-1 cells, infected at two multiplicities of infection with HSV-1716 and injected i.p. at 5 x 10⁶ cells/animal, led to a significant tumor reduction in the two models tested and the significant prolongation of mean survival in one model. Histological evaluation revealed extensive necrosis in tumor areas infected by HSV-1716. Immunohistochemistry against HSV-1 revealed areas of viral infection within tumor nodules, which persisted for several weeks after treatment. Administration of HSV-infected PA-1 carrier cells resulted in larger areas of tumor infected by the virus. Our results indicate that replication-competent attenuated HSV-1 exerts a potent oncolytic effect on EOC, which may be further enhanced by the utilization of a delivery system with carrier cells, based on amplification of the viral load and possibly on preferential binding of carrier cells to tumor surfaces.

This article has been cited by other articles:

				L. BRAIDWOOD, P. D. DUNN, S. HARDY, T.R. J. EVANS, and S. M. BROWN Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy Anticancer Res, June 1, 2009; 29(6): 2159 - 2166. [Abstract] [Full Text] [PDF]

				S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766. [Abstract] [Full Text] [PDF]

				M. Navo and J. A. Smith Update on the Prevention and Treatment of Ovarian Cancer Journal of Pharmacy Practice, June 1, 2003; 16(3): 149 - 156. [Abstract] [PDF]

				G. Coukos, A. Makrigiannakis, E. H. Kang, S. C. Rubin, S. M. Albelda, and K. L. Molnar-Kimber Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3342 - 3353. [Abstract] [Full Text]

				E. S. Lambright, D. J. Caparrelli, A. E. Abbas, T. Toyoizumi, G. Coukos, K. L. Molnar-Kimber, and L. R. Kaiser Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system Ann. Thorac. Surg., November 1, 1999; 68(5): 1756 - 1760. [Abstract] [Full Text] [PDF]